New Mexico Educational Retirement Board Acquires Shares of 19,200 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

New Mexico Educational Retirement Board acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 19,200 shares of the biotechnology company’s stock, valued at approximately $3,034,000.

Other large investors also recently made changes to their positions in the company. Arizona State Retirement System lifted its position in Sarepta Therapeutics by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 23,647 shares of the biotechnology company’s stock worth $3,736,000 after buying an additional 509 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Sarepta Therapeutics by 15.4% during the second quarter. Victory Capital Management Inc. now owns 83,073 shares of the biotechnology company’s stock worth $13,126,000 after purchasing an additional 11,087 shares in the last quarter. National Bank of Canada FI lifted its position in shares of Sarepta Therapeutics by 5.2% during the second quarter. National Bank of Canada FI now owns 7,527 shares of the biotechnology company’s stock worth $1,180,000 after purchasing an additional 369 shares in the last quarter. Ferguson Shapiro LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $228,000. Finally, Oregon Public Employees Retirement Fund acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at approximately $3,097,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $128.92 on Friday. The stock’s fifty day simple moving average is $142.50 and its 200 day simple moving average is $133.09. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $12.19 billion, a PE ratio of 1,172.00 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same quarter last year, the firm posted ($0.27) earnings per share. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. On average, research analysts predict that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Barclays decreased their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Citigroup decreased their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Mizuho lifted their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Leerink Partners upped their target price on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Three analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $186.22.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the sale, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now directly owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,801 shares of company stock valued at $8,399,586. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.